Skip to Content

Palbociclib As First-Line Breast Cancer Treatment: A Danish Perspective

This Danish study aimed to assess the impact of age and comorbidities on PFS and OS for patients with ER-positive, HER2 normal, advanced breast cancer treated with palbociclib and AI. In this MEDtalk, Alan Celik, MD, Danish Breast Cancer Group (DBCG), presents the results from the study.

Alan Celik

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top